Bristol Myers Squibb (BMY) Announces Amphista Therapeutics Collaboration

Last Updated: Wednesday, May 4, 2022 10:18 AM | Nick Dey

Morning News Leader

Bristol Myers Squibb (BMY) announced a strategic collaboration with Amphista Therapeutics to discover and develop small molecule protein degraders, which grants Bristol Myers a global exclusive license to the degraders. Targeted protein degradation (TPD) therapeutics remove pathogenic proteins from the body to potentially offer access to disease targets previously considered "undruggable".

InvestorsKeyhole Trade Alert

Share this article:

Related Companies

You May Also Like

Related Articles

McKesson Corp (MCK) Stock by the Numbers

Davita Inc (DVA) is lower by -3.94% in a Week, Should You Accumulate?

Can Iqvia Holdings Inc (IQV) Stock Rise to the Top of Healthcare Sector Friday?

Is Viatris Inc (VTRS) Stock a Good Value Friday?

Will Cooper Companies Inc (COO) Outperform the Rest of the Stocks in the Healthcare Sector?

Illumina, Inc. (ILMN) Stock: Do Analysts Think You Should Sell?

Related Companies